Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effect of dexamethasone intravitreal implant in a corneal graft rejection.

Literature DB >> 27158625

Effect of dexamethasone intravitreal implant in a corneal graft rejection.

Nilufer Yesilirmak¹, Evin Singar Ozdemir², Dilek D Altinors³.

Abstract

Entities: Chemical

Year: 2016 PMID： 27158625 PMCID： PMC4844032 DOI： 10.18240/ijo.2016.03.28

Source DB: PubMed Journal: Int J Ophthalmol ISSN： 2222-3959 Impact factor: 1.779

× No keyword cloud information.

14 in total

1. [Ozurdex(®) and aphakia: a combination to avoid].

Authors: C Marín-Lambíes; R Gallego-Pinazo; S García-Delpech; M Díaz-Llopis
Journal: Arch Soc Esp Oftalmol Date: 2012-03-10

2. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.

Authors: Joan-En Chang-Lin; James A Burke; Qing Peng; Ton Lin; Werhner C Orilla; Corine R Ghosn; Kai-Ming Zhang; Baruch D Kuppermann; Michael R Robinson; Scott M Whitcup; Devin F Welty
Journal: Invest Ophthalmol Vis Sci Date: 2011-06-28 Impact factor: 4.799

3. Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®).

Authors: Diamar Pardo-López; Ester Francés-Muñoz; Roberto Gallego-Pinazo; Manuel Díaz-Llopis
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2011-08-23 Impact factor: 3.117

4. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.

Authors: Joan-En Chang-Lin; Mayssa Attar; Andrew A Acheampong; Michael R Robinson; Scott M Whitcup; Baruch D Kuppermann; Devin Welty
Journal: Invest Ophthalmol Vis Sci Date: 2011-01-05 Impact factor: 4.799

5. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal: Ophthalmology Date: 2010-04-24 Impact factor: 12.079

6. Case-control study of subconjunctival triamcinolone acetonide injection vs intravenous methylprednisolone pulse in the treatment of endothelial corneal allograft rejection.

Authors: D C Costa; R S de Castro; N Kara-Jose
Journal: Eye (Lond) Date: 2008-09-26 Impact factor: 3.775

Effect of dexamethasone intravitreal implant in a corneal graft rejection.

1. [Ozurdex(®) and aphakia: a combination to avoid].

2. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.

3. Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®).

4. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.

5. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

6. Case-control study of subconjunctival triamcinolone acetonide injection vs intravenous methylprednisolone pulse in the treatment of endothelial corneal allograft rejection.

7. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies.

8. Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant.

Review 9. Sustained-release corticosteroid options.

10. Influential factors on the survival of endothelial cells after penetrating keratoplasty.

1. Long-lasting corneal endothelial graft rejection successfully reversed after dexamethasone intravitreal implant.